Title of study: Clinical trial of a new topical treatment for alopecia areata
A clinical trial to test a new topical treatment for alopecia areata
11 January 2022
A new clinical trial has opened and is recruiting study volunteers who have mild-to-moderate alopecia areata (patchy hair loss NOT totalis or universalis). The trial aims to test a new topical product based on a mechanism with a well established safety profile in dermatology, and existing evidence of efficacy in treating alopecia areata. The product has been modified to maximise the efficacy of this mechanism, and offer a cosmetically elegant topical cream.
If the trial is successful, the intention is to gain approval for mild/moderate alopecia areata so that it can be prescribed to all patients.
The aim of the study is to see how effective the new product is in inducing hair regrowth.
Who can take part?
Age 18 or over.
With a current episode of patchy alopecia areata lasting more than 6 months
Able to read and write in English
Be generally in good health and not planning to become pregnant
Not be using any other alopecia treatments for at least 6 weeks (or 3 months depending on medication).
What will it involve?
The person with alopecia areata will be invited to attend clinics in the UK and asked to give consent to receive either cream containing the new topical product, or a cream that doesn't contain it (the ‘dummy’ or placebo treatment). They will not know which type of cream they have, so as not to influence the results. They will be asked to apply their cream to the affected skin every day for 6 months and will then be followed up for a further 2 months. They will be assessed by a health care professional and asked to complete a questionnaire about the treatment and their quality of life.
to find out more and apply to take part.